MicroBlate™ Fine commercial update

Creo Medical Group PLC

07 May 2026

 

Creo Medical Group plc

("Creo", the "Company" or the "Group")

MicroBlate™ Fine commercial update

Creo Medical accelerates US clinical adoption and commercial rollout of MicroBlate Fine

First breakthrough case delivering targeted therapy for pancreatic lesions

Creo Medical Group plc (AIM: CREO), the medical device company specialising in advanced energy solutions for therapeutic endoscopy, announces a clinical and commercial update on MicroBlate Fine, its precision microwave ablation platform, as momentum builds across early US clinical adoption and commercial rollout.

MicroBlate Fine has now crossed the threshold of 50 clinical cases worldwide across multiple institutions, with particularly strong engagement from leading US interventional endoscopy centres. MicroBlate Fine is being further evaluated through an international investigator‑led study across the US, Europe and Asia‑Pacific, with Banner Health in the US acting as the principal investigative site. The study is targeting patients with pancreatic and liver lesions. The first patient was treated in March 2026.

In the US, MicroBlate Fine has recently been used to perform the first endoscopic ultrasound ("EUS") guided microwave ablation of a pancreatic lesion, highlighting its applicability in complex and previously difficult‑to‑treat anatomy. MicroBlate Fine enables EUS‑guided microwave ablation through a flexible 19G needle, providing precise, controlled and homogeneous energy delivery while integrating seamlessly into existing EUS workflows. The device is powered by Creo's CROMA™ Advanced Energy Platform.

Early adoption by US centres of excellence plays a critical role in accelerating broader market acceptance and supports future commercial scale‑up in what represents one of the world's largest therapeutic endoscopy markets. MicroBlate Fine provides a strategic entry point into high‑value microwave ablation procedures, with the potential to enhance recurring revenues and increase utilisation of Creo's broader advanced energy ecosystem, particularly in the US market.

The Company expects continued expansion of site adoption through 2026, alongside growing US clinical engagement, supporting both near‑term revenue generation and longer‑term market penetration in advanced therapeutic endoscopy.

Dr Shailendra Singh, Director of Advanced Endoscopy and Associate Professor at West Virginia University, said: "The ability to deliver microwave ablation under EUS guidance offers precise, controlled and homogeneous energy delivery, enabling targeted therapy for pancreatic lesions. Technologies such as this expand the reach of interventional EUS and have the potential to significantly broaden treatment options for patients."

Craig Gulliford, Chief Executive Officer of Creo Medical, said: "Early US clinical engagement with MicroBlate Fine, combined with progressing international studies and encouraging commercial traction, reinforces our belief that this product can become an important growth driver for the Group. With attractive per‑procedure economics and clear portfolio pull‑through, MicroBlate Fine strengthens our position in therapeutic endoscopy and enhances our commercial opportunity.

"As always, patient benefits come first and the fact that previously very sick patients are being put back on to routine follow-up with no evidence of disease at their first follow-up consultation is extremely rewarding for the whole Creo Team."

For further information please contact: 

Creo Medical Group plc		www.creomedical.com
Richard Craven, Company Secretary		Via Walbrook PR
Deutsche Numis (Nominated Adviser, Joint Broker and Financial Adviser) Duncan Monteith / Sher Shah		[phone]
Shore Capital (Joint Broker) Daniel Bush / Lucy Bowden		[phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus / Alice Woodings	Mob: [phone]

About Creo Medical

Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com

 

END